VCP
AQST icon

Verus Capital Partners’s Aquestive Therapeutics AQST Stock Holding History

Verus Capital Partners’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$158K Sell
38,100
-13,525
-26% -$56.9K 0.01% 482
2026
Q1 		$214K Buy
51,625
+21,225
+70% +$86.1K 0.01% 427
2025
Q4 		$196K Buy
30,400
+13,600
+81% +$84.7K 0.01% 430
2025
Q3 		$93.9K Buy
+16,800
New +$72.6K 0.01% 411

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Verus Capital Partners's AQST Position: Q2 2026 in Review

Verus Capital Partners reduced its Aquestive Therapeutics (AQST) stake by 26% in Q2 2026, selling an estimated $56.9K and leaving 38,100 shares worth $158K. The position accounts for 0.01% of the portfolio, ranked #482.

Verus Capital Partners first reported a position in AQST in Q3 2025 and has held it in 4 quarters since. The position peaked at $214K in Q1 2026. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Verus Capital Partners held 38,100 shares of Aquestive Therapeutics worth $158K as of Q2 2026.
  • Verus Capital Partners sold 13,525 Aquestive Therapeutics shares in Q2 2026, an estimated $56.9K.
  • Aquestive Therapeutics made up 0.01% of Verus Capital Partners's portfolio in Q2 2026, its #482 holding.
  • Verus Capital Partners first reported a position in Aquestive Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Verus Capital Partners's Aquestive Therapeutics position peaked at $214K in Q1 2026.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Verus Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.